deltatrials
Completed PHASE3 NCT00047736

A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer

A Phase III, Randomized, Double Blind, Multicenter Trial of Tarceva (Erlotinib) Plus Chemotherapy (Carboplatin and Paclitaxel) Versus Chemotherapy Alone in Patients With Advanced (Stage IIIb or IV) Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

Sponsor: Genentech, Inc.

Conditions Lung Cancer
Interventions Tarceva (erlotinib HCl)
Updated 5 times since 2017 Last updated: Jun 19, 2013 Started: Jul 31, 2001 Completion: Jul 31, 2003

This PHASE3 trial investigates Lung Cancer and is currently completed. Genentech, Inc. leads this study, which shows 5 recorded versions since 2001 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Jul 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genentech, Inc.
Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Denver, United States